|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-5-30
|
|
pubmed:abstractText |
Cisplatin-based concurrent chemoradiotherapy is the standard treatment of nasopharyngeal cancer. The expression of excision repair cross-complementation group 1 (ERCC1) has been reported to be associated with resistance to platinum-based chemotherapy. We evaluated whether ERCC1 expression could predict the treatment response and survival outcome of patients with locally advanced nasopharyngeal cancer who were treated with cisplatin-based concurrent chemoradiotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1879-355X
|
|
pubmed:author |
pubmed-author:AhnJin SeokJS,
pubmed-author:AhnMyung-JuMJ,
pubmed-author:AhnYong ChanYC,
pubmed-author:BaekChung-HwanCH,
pubmed-author:HanJounghoJ,
pubmed-author:KangGuG,
pubmed-author:LeeHui-YoungHY,
pubmed-author:LeeSeungkooS,
pubmed-author:ParkKeunchilK,
pubmed-author:ParkMin JaeMJ,
pubmed-author:SonYoung-IkYI,
pubmed-author:SunJong-MuJM
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
80
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
655-60
|
|
pubmed:meshHeading |
pubmed-meshheading:21621119-Adolescent,
pubmed-meshheading:21621119-Adult,
pubmed-meshheading:21621119-Aged,
pubmed-meshheading:21621119-Analysis of Variance,
pubmed-meshheading:21621119-Antineoplastic Agents,
pubmed-meshheading:21621119-Carcinoma,
pubmed-meshheading:21621119-Cisplatin,
pubmed-meshheading:21621119-Combined Modality Therapy,
pubmed-meshheading:21621119-Confidence Intervals,
pubmed-meshheading:21621119-DNA-Binding Proteins,
pubmed-meshheading:21621119-Disease-Free Survival,
pubmed-meshheading:21621119-Drug Resistance, Neoplasm,
pubmed-meshheading:21621119-Endonucleases,
pubmed-meshheading:21621119-Female,
pubmed-meshheading:21621119-Humans,
pubmed-meshheading:21621119-Male,
pubmed-meshheading:21621119-Middle Aged,
pubmed-meshheading:21621119-Nasopharyngeal Neoplasms,
pubmed-meshheading:21621119-Tumor Markers, Biological,
pubmed-meshheading:21621119-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy.
|
|
pubmed:affiliation |
Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
|
|
pubmed:publicationType |
Journal Article
|
